Pfizer Faces Sharp Revenue Cliff, Pivots to Oncology Amid Vaccine Slump

Pfizer is accelerating its strategic pivot to offset the massive revenue cliff from its COVID-19 portfolio, highlighted by its recent acquisition of Seagen to bolster its oncology pipeline. Beyond cancer treatments, the pharmaceutical giant is diversifying its vaccine offerings through significant investments in areas such as the Respiratory Syncytial Virus (RSV) vaccine. These initiatives are part of an ambitious long-term roadmap to field more than 20 blockbuster drugs by 2030. This transition follows a sharp decline in Comirnaty revenue, which is projected to fall from over $37 billion in 2022 to less than $10 billion by 2025. Market analysts are closely monitoring Pfizer's ability to execute these acquisitions and R&D expansions to secure sustainable growth drivers in the post-pandemic era.